Gri bio commences patient enrollment in phase 2a biomarker study evaluating lead program gri-0621 for the treatment of idiopathic pulmonary fibrosis (“ipf”)

Clinical development plan potentially leveraging 505(b)(2) regulatory pathway currently available treatments for ipf are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 1 la jolla, ca, dec. 05, 2023 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (“nkt”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the initiation of patient enrollment in the phase 2a biomarker study evaluating gri-0621 for the treatment of ipf. patient dosing is expected imminently.
GRI Ratings Summary
GRI Quant Ranking